Suppr超能文献

重复注射A型肉毒杆菌毒素治疗骨髓发育不良儿童及脊髓损伤伴神经源性膀胱功能障碍患者。

Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.

作者信息

Akbar Michael, Abel Rainer, Seyler Thorsten M, Bedke Jens, Haferkamp Axel, Gerner Hans J, Möhring Klaus

机构信息

Department of Orthopaedic Surgery, University of Heidelberg, Heidelberg, Germany.

出版信息

BJU Int. 2007 Sep;100(3):639-45. doi: 10.1111/j.1464-410X.2007.06977.x. Epub 2007 May 26.

Abstract

OBJECTIVES

To examine the effects of repeated detrusor injections of botulinum-A toxin (BTX) for possible changes in bladder function, muscular structure of the detrusor, increase in BTX tolerance (tachyphylaxis) and side-effects, as BTX is a new treatment alternative for patients with a neurogenic bladder condition that is difficult to treat and refractory to anticholinergic medication.

PATIENTS AND METHODS

Between 2000 and 2005, 19 patients with myelodysplasia (MDP) and 25 spinal cord-injured (SCI) patients were treated with repeated suburothelial BTX injections (Dysport, Ipsen-Pharma, Ettlingen, Germany) or injections into the intramural detrusor. The follow-up was > or = 3 years (range 3-5, median 4.5).

RESULTS

Detrusor compliance, bladder capacity, and detrusor pressure at maximum filling improved significantly (P < 0.001) compared to baseline after each BTX injection. There was prolonged efficacy of each BTX administration and all repeated injections in the paediatric and adult patients with neurogenic bladder dysfunction over a median follow-up of 4.5 years. There was no evidence for drug tolerance or changes in the morphological appearance of the bladder. Safety was good: no complications were associated with the injection procedure itself. Early in the treatment programme, three patients who received a dose of 1000 units Dysport showed systemic side-effects and generalized muscle weakness. These resolved without intervention and did not recur after reducing the adult dose to 750 units (paediatric dose 20 units/kg, not >400 units), which seems to be the optimum for good efficacy with an adequate safety margin.

CONCLUSION

BTX injection is a safe and effective treatment for neurogenic detrusor hyperreflexia. Repeat treatments are as effective as the first: there was no indication of a lack of efficacy due to tachyphylaxis, antibody formation, or fibrosis of the detrusor muscle in this sample.

摘要

目的

肉毒杆菌A毒素(BTX)是治疗难治性神经源性膀胱疾病患者的一种新的治疗选择,本研究旨在探讨反复向逼尿肌注射BTX对膀胱功能、逼尿肌肌肉结构、BTX耐受性增加(快速耐受)及副作用的影响。

患者与方法

2000年至2005年间,19例脊髓发育不良(MDP)患者和25例脊髓损伤(SCI)患者接受了反复的膀胱黏膜下BTX注射(Dysport,益普生制药公司,德国埃特林根)或壁内逼尿肌注射。随访时间≥3年(范围3 - 5年,中位数4.5年)。

结果

与每次BTX注射前的基线相比,逼尿肌顺应性、膀胱容量和最大充盈时的逼尿肌压力均显著改善(P < 0.001)。在中位随访4.5年期间,对于患有神经源性膀胱功能障碍的儿童和成人患者,每次BTX给药及所有重复注射均有延长的疗效。没有证据表明存在药物耐受性或膀胱形态外观的改变。安全性良好:注射过程本身未出现并发症。在治疗方案早期,3例接受1000单位Dysport剂量的患者出现全身副作用和全身肌肉无力。这些症状未经干预自行缓解,在将成人剂量降至750单位(儿童剂量20单位/千克,不超过400单位)后未再次出现,这似乎是具有足够安全边际的良好疗效的最佳剂量。

结论

BTX注射是治疗神经源性逼尿肌反射亢进的一种安全有效的方法。重复治疗与首次治疗效果相同:在本样本中,没有迹象表明由于快速耐受、抗体形成或逼尿肌纤维化导致疗效不佳。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验